Camposol Holding PLC will announce its preliminary financial results for the third quarter of 2025 on Wednesday, November 26, 2025, at 9:00 a.m. Eastern Time (ET). In connection with this release, Ricardo Naranjo Fernandez, CEO, and Jossue Yesquen Lihim, IRO, will host a conference call presentation and Q&A session. To register and participate in the conference call please use the following link: https://register-conf.media-server.com/register/BIcd23eb97c328417c99dcf2bfc1fd4b33 Participants are advised to log in to the conference call service and check their audio and system settings a few minutes before the conference call begins. To access the webcast presentation associated with the conference call, please click on the following link: https://edge.media-server.com/mmc/p/i79eb45v If you are unable to participate in the conference...

2025 Full Year Sales Guidance Down 10% to 12% from Prior Year, and Well-Positioned to Accelerate 2026 New Program Launches COLUMBUS, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reports financial and operating results for the fiscal periods ended September 30, 2025. David Duvall, the Company’s President and Chief Executive Officer, and Eric Palomaki, Chief Operating Officer, commented, “While topline challenges persist, we are enthusiastic about Core Molding’s Invest for Growth achievements, highlighted...

GREENWICH, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) — Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQG) (NasdaqGS: OXSQH) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended September 30, 2025.On October 30, 2025, our Board of Directors declared the following distributions on our common stock:Month Ending Record Date Payment Date Amount Per ShareJanuary 31, 2026 January 16, 2026 January 30, 2026 $0.035February 28, 2026 February 13, 2026 February 27, 2026 $0.035March 31, 2026 March 17, 2026 March 31, 2026 $0.035 Net asset value (“NAV”) per share as of September 30, 2025 stood at $1.95, compared with a NAV per share on June 30, 2025 of $2.06.Net investment income (“NII”) was approximately $5.6 million, or $0.07 per share, for the...

OAK BROOK, Ill., Nov. 04, 2025 (GLOBE NEWSWIRE) — Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the one-of-a-kind restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the third quarter ended September 28, 2025. Third Quarter 2025 Performance Highlights (vs. Third Quarter 2024):Total revenue of $181.4 million, an increase of 1.8% or $3.2 million Same-restaurant sales decrease of -0.8% Operating income of $5.4 million, a decrease of $10.6 million Net income of $0.8 million, a decrease of $8.0 million Restaurant-Level Adjusted EBITDA(1) of $36.7 million, a decrease of $5.3 million Adjusted EBITDA(1) of $21.4 million, a decrease of $6.5 million(1) Adjusted EBITDA and Restaurant-Level Adjusted EBITDA are non-GAAP measures. Please see definitions and the reconciliations...

Third Quarter 2025 Revenue of $84.2 Million Third Quarter 2025 Net Income Attributable to Cohen & Company Inc. of $4.6 Million, or $2.58 per Diluted Share Third Quarter 2025 Adjusted Pre-Tax Income of $16.4 Million, or $2.71 per Diluted Share Board Declares Quarterly Dividend of $0.25 per Share PHILADELPHIA and NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Cohen & Company Inc. (NYSE American: COHN), a financial services firm specializing in an expanding range of capital markets and asset management services, today reported financial results for its third quarter ended September 30, 2025. Summary Operating Results  Three Months Ended   Nine Months Ended($ in thousands) 9/30/25   6/30/25   9/30/24   9/30/25   9/30/24                   Net trading $ 13,560     $ 10,757     $ 8,816     $ 33,528     $ 27,462  Asset...

Business Wins and Strategic Initiatives Drove Revenue Growth While Demand Remained Stable  Higher Revenue Resulted in Gross Margin Improvement MARLBOROUGH, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the third quarter ended September 30, 2025.    Three Months Ended September 30,       Nine Months Ended September 30,      (In millions, except per share data and percentages)     2025       2024     Change     2025       2024     Change  Revenue   $ 250.8     $ 233.1     8 %   $ 729.3     $ 742.8     (2 )%Gross margin     39.5 %     23.2 %         38.7 %     33.4 %      Operating income (loss)   $ 7.9     $ (253.3 )   NM     $ 9.8     $ (222.2 )   NM  Operating margin     3.1 %   (108.7 )%         1.3 %     (29.9 )%      Net income (loss)   $ 7.5     $ (233.6 )   NM     $ 17.8     $ (189.3 )   NM  Earnings...

Reiterates 2025 Outlook for Consolidated Revenue and Adjusted EBITDA Strengthened Balance Sheet and Extended Maturity Profile Through Recent FinancingsNet Income of $1.609 Billion for the Third Quarter Includes One-Time Gain Related to Merger with Windstream Consolidated Revenue and Adjusted EBITDA of $722.6 Million and $327.8 Million, Respectively, for the Third Quarter____________________________ LITTLE ROCK, Ark., Nov. 04, 2025 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced its results for the third quarter 2025. Key highlights during the quarter included:Consolidated Fiber Revenue Grew 13% Year-over-Year in the Third Quarter Kinetic Consumer Fiber Revenue Grew 26% Year-over-Year in the Third Quarter Kinetic Consumer Fiber Subscribers Grew 17% Year-over-Year in the Third Quarter Kinetic...

Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million – $163 million and adjusted EBITDA of $9.0 – $13.0 million ZYNRELEF® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributors APONVIE® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2025 and recent corporate...

Third quarter net income of $17.7 millionThird quarter Adjusted EBITDA of $39.3 millionDredging backlog of $934.5 million at September 30, 2025 HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (Nasdaq: GLDD), the largest provider of dredging services in the United States, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 HighlightsRevenue was $195.2 million Total operating income was $28.1 million Net income was $17.7 million Adjusted EBITDA was $39.3 million Dredging backlog as of September 30, 2025 was $934.5 millionManagement Commentary Lasse Petterson, President and Chief Executive Officer, commented, “Great Lakes delivered another solid quarter, driven by strong project execution and high equipment utilization....

FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows:NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-end NXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosing NXP900 clinical drug-drug interaction study in healthy volunteers successfully completed supporting our strategy for combination therapy Poster...